Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Kirsty on +44 1494 818057 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Kirsty Morris
Senior Account Manager
+44 1494 818057

I have a lot of experience as a Regional Business Manager, and have been involved in recruitment for the last twenty years or so, therefore, I pride myself in knowing who are the good recruiters.
Jeff, 2012

Bayer HealthCare wins NICE recommendation for Xarelto

2 April 2012 00:00 in Pharmaceutical Company Product News

Bayer HealthCare's promising new therapy Xarelto has been granted a recommendation from the UK's National Institute for Health and Clinical Excellence (NICE).

Draft guidance from the regulatory body has endorsed the rivaroxaban treatment for NHS use in England and Wales against stroke and systemic embolism among certain patients with non-valvular atrial fibrillation.

The drug has been shown to offer safety and efficacy benefits among atrial fibrillation sufferers affected by one or more risk factors, such as congestive heart failure, hypertension, old age, diabetes mellitus and prior stroke history.

Final guidance on Xarelto is expected as early as this month, with Bayer to work alongside NHS fundholders to incorporate the therapy into local services.

Luis-Felipe Graterol, medical director for Bayer HealthCare UK, said: "Xarelto has the potential to make a positive difference to NHS anticoagulation services by helping simplify clot prevention, particularly for the one-third of patients who are not currently achieving an adequate level of stroke protection with warfarin."

This comes after the company published phase III clinical trial data last month showing Xarelto's efficacy as a therapy for pulmonary embolism.ADNFCR-8000103-ID-801331439-ADNFCR

Other news stories from 02/04/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd